SNAP Update and ResourcesActualización y recursos de SNAP
On November 1, 2025, the requirements to receive and apply to the Supplemental Nutrition Assistance Program (SNAP) benefits have changed. To see the new policies to request SNAP benefits, click here and/or call 211 for SNAP assistance. Learn more
El 1 de noviembre de 2025, cambiaron los requisitos para recibir y aplicar para los beneficios del Programa de Asistencia Nutricional Suplementaria (SNAP, por sus siglas en inglés). Para consultar las nuevas políticas para aplicar para los beneficios de SNAP, haz clic aquí o llama al 211 para obtener ayuda de SNAP. Aprende Más
Transportation UpdateActualización de transporte
Starting December 15, 2025, SafeRide Health will become the new provider for all member rides to doctor appointments and pharmacy visits. After this date, Texas Children’s Health Plan will no longer use MTM for Non Emergency Medical Transportation (NEMT) services.
For other questions, please call Member Services at the number on the back of your member ID card.
A partir del 15 de diciembre de 2025, SafeRide Health será el nuevo proveedor para todos los viajes de los miembros a citas médicas y visitas a la farmacia. Después de esta fecha, Texas Children’s Health Plan ya no usará MTM para los servicios de Transporte Médico No Urgente (NEMT).
Date: January 14, 2022
Attention: Oncology Providers
Effective Date: March 1, 2022Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated to the COVID-19 event. TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event.
Call to action: Beginning March 1, 2022, Benlysta (procedure code J0490) will be available for Medicaid members as a medical benefit. Benlysta (belimumab) is indicated to treat active, autoantibody-positive, systemic lupus erythematosus (SLE) in clients 5 years of age and older who are receiving standard SLE therapy. Benlysta is also indicated to treat lupus nephritis in adult clients, 18 years of age and older who are on standard therapy.
How this impacts providers: There are no prior authorization criteria, but there are age/diagnosis restrictions for Benlysta (belimumab) J0490 infusion therapy:
For systemic lupus erythematosus:
The client is 5 years of age and older.
The client has a confirmed diagnosis of systemic lupus erythematosus (diagnosis codes: M3210, M3211, M3212, M3213, M3214, M3215, M3219, M328, M329).
For active lupus nephritis:
The client is 18 years of age and older.
The client has a diagnosis of active lupus nephritis
Next steps for providers: Prescribers should adjust their prescribing patterns accordingly and communicate these changes to their staff.
If you have any questions, please email TCHP Department at: TCHPPharmacy@texaschildrens.org.
For access to all provider alerts,log into:
www.thecheckup.org or www.texaschildrenshealthplan.org/for-providers.
